Velbastine Caution For Usage

Vinblastine Sulfate should be administered intravenously only. Intrathecal administration may result in death.
Vinblastine Sulfate should be given intravenously at weekly intervals. The use of small amounts of Vinblastine Sulfate daily for long periods is not advised, even though the resulting total weekly dosage may be similar to that recommended. No added therapeutic effect has been demonstrated and adverse effects (i.e. convulsions, severe CNS toxicity) have been observed when such regimens have been used.
It is extremely important that the needle be properly positioned in the vein before this product is injected. If leakage into surrounding tissue should occur during intravenous administration of Vinblastine Sulfate, it may cause considerable irritation. The injection should be discontinued immediately, and any remaining portion of the dose should then be introduced into another vein. Local injection of hyaluronidase and the application of moderate heat to the area of leakage help disperse the drug and are thought to minimize discomfort and the possibility of cellulitis. Care must be taken to avoid contamination of the eye with concentrations of Vinblastine Sulfate used clinically. If accidental contamination occurs, severe irritation or corneal ulceration may result. The eye should be washed with water immediately and thoroughly.
The dose should not be diluted in large volumes of diluent (100 to 200 mL) or given intravenously for prolonged periods (ranging from 30 to 60 minutes or more), since this frequently results in irritation of the vein and increases the chance of extravasation.